LivingGLP1
Study S002653

The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT02694575
Acronym
IGLOOS
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
241
Start
2015-03-01
Primary completion
2017-04-12
Lead sponsor
University of Leicester
Conditions
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • EPC [Single sample analysis - no time frame]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0027258Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck MA, Diabetologia
2011Narrative reviewPMID 20871975DOIregistry reference BACKGROUND:20871975
R0014510Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Arakawa M, Diabetes
2010PreclinicalPMID 20068138DOIregistry reference BACKGROUND:20068138
R0023270Exenatide versus glibenclamide in patients with diabetes.
Derosa G, Diabetes technology & therapeutics
2010Randomized trialPMID 20151774DOIregistry reference BACKGROUND:20151774
R0014170The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ, Lancet (London, England)
2006Narrative reviewPMID 17098089DOIregistry reference BACKGROUND:17098089